

Index

Page numbers in bold type, e.g. **38–45**, indicate detailed discussion of the topic.

A

- accidents, 43–5, 131, 134–6, 202, 208, 212, 222; *see also* driving
- acute health effects, 36, **38–45**, 131, 134, 209, 212–14
- acute psychological effects, **38**, 45, 119, 213–14
- addiction *see* drug dependence
- administration, methods of, 6, **14**, 38, 130, 135, 140, 228, 232; *see also* cannabis smoking; injection; oral administration
- administrative sanctions *see* civil sanctions
- adolescents: accidents, 44; cannabis as gateway drug, **104–14**, 216; cannabis dependence, 75–6, 78, 125; cannabis use, 18–26, 28–9, 78, 90, 93, 96, 140, 159, 208; cognitive effects, 125; complementary drug use, 153; crime, 237–9; decriminalisation and use, xi, 222; delinquency and crime, 124–5; deterrence, 2, 157; drug substitution, 145; effects of cannabis use, xii, 216; effects on development, 101–25, 224; employment, 125; enforcement, 125, 168; health effects, 132; heavy users, 125; home cultivation, 210; interpersonal relationships, 121; intoxication, 125; law reform and use, 198, 201–2, 209–10, 211–12, 223–5; life opportunities, 125; mental health, 121–3, 125, 143–4; occupational performance, 120–1; problem behaviour, 116, 239; psychological outcomes, 70, 115–25; psychosocial outcomes, 35, 216; recreational use, 147; reproductive effects, 53; schizophrenia, 137; suicide, 123–4; *see also* disrespect for law; educational performance; young adults
- adulthood, transition to, 103, 119–21, 163, 211, 223
- adults: benefits of recreational cannabis use, 142, 153; cardiovascular effects, 61, 215; cognitive effects, 119; crime, 124; deterrence, 161, 164; legal use, 197–8; patterns of use, 21–9; prohibition of use, 1; psychotic disorders, 96; *see also* young adults
- adverse health effects, 1–5, 31–65, 130, 136, 138, 222, 225; alternative explanations, 34–5; education, 179–80; high-risk groups, 132; prohibition and, 159, 216–17; psychological effects, 69; *see also* acute health effects; chronic health effects
- aerodigestive tract cancers, 47–9, 58, 64–5, 131, 135, 214
- affective disorders, 122, 142–3
- Africa, cannabis use in, 26–8
- age: cannabis dependence and, 75; cannabis use and, 18–25, 26–7; early adolescent use, 125; first use, 104, 108–9, 113, 117–20, 124–5, 132–3, 216; legal drinking age, 144–5, 160; restrictions on use, 202, 205, 209–10, 218, 222
- aggression *see* violence and aggression
- AIDS *see* HIV-AIDS
- alcohol: benefits of moderate use, 142–3; cognitive impairment, 85; crime, 236–8; dependence, 71, 75, 77–8, 90, 98, 109, 122–5, 132, 135, 215; driving under the influence (*see* driving); educational performance, 117–18; gateway hypothesis, 104, 106–7, 111–13, 216; health effects,

- 5–6, 129, 130–41, 213, 217; legal restrictions, 201–4, 207, 222; mental health benefits of moderate use, 153, 222; mental health of adolescents, 122, 219; patterns of use, 21–2, 160, 211; policy, x, 3–4, 223–4; pregnancy, 81; price, 208, 212; prohibition, 7, 157–8, 188, 190; psychomotor performance, 39–45; psychotic disorders, 89–91, 97–8; recreational use, 142; regulation, 201, 207, 222; risks, 136, 141; social cost, 208–9; substitution of cannabis for, 144–6; suicide, 123–4; use in combination with cannabis, 37, 41–5, 47–8, 56–8, 79, 81, 84, 89–91, 133, 136, 141, 208, 214; violence, 131
- allergies, 51
- amotivational syndrome, 70–1, 78, 119
- amphetamines, 37, 93, 104, 112–13, 189, 216
- analgesic effects, 60, 146–8, 151–2, 180–1, 219, 227–8, 230, 232–3
- animal evidence: cannabinoid receptors, 17; cardiovascular effects, 60; cellular processes, 46–7, 58; cross-sensitivity of drugs, 114; gastrointestinal effects, 65; health effects, 34–5, 37; immunological effects, 37, 50–2, 58, 214; medical uses, 147, 149–51, 153; pharmacology, 110–11, 114; reproductive effects, 53–5, 57, 214; tolerance, 72; toxicity, 39
- anti-convulsant use, 146–7, 149–50
- anti-emetic use, 65, 146–8, 150, 152–3, 180–1, 219, 227, 232–3
- anti-spasmodic use, 146–7, 149–50, 154, 180–1, 219, 232–3
- antisocial behaviour, 106, 115, 122, 125
- anxiety: adverse effect of cannabis use, 36, 38–9, 45, 73, 91, 98, 122, 131, 143, 213; benefit of moderate alcohol use, 142; medical uses, 151
- appetite stimulation, 17, 53, 65, 147–8, 152–4, 180, 215, 219, 227
- arthritis, 233
- Asia, cannabis use in, 26–8
- asthma, 132, 151
- attention, 38, 79, 81–3, 85, 115, 119, 131, 213, 215
- Australia: adolescent cannabis use, 104–5, 109, 115, 122–3; benefits of cannabis use, 142–4, 176; cannabis dependence, 74, 76, 78; cannabis use, 4, 23–5, 28–9, 159–62; car accidents, 42–3; crime, 236–8; drug dependence, 78; drug substitution, 146; immunological effects, 53; medical uses, 181, 219, 232–3, 234; methods of use, 14; policies, 1, 165–7, 169, 171, 174–9, 191–2, 196–7, 200, 210, 220–2; potency of cannabis, 133; price, 200; psychotic disorders, 90–1, 99; public health, 138–9, 201; schizophrenia, 99
- Austria, 167
- availability, 108, 112–13, 190, 205, 211
- B**
- behavioural effects, 59, 213, 215
- Belgium, x, 28
- benefits of cannabis use, xi, 129, 142–52, 153, 176, 219, 224
- birth defects, 55–7, 59, 134, 215
- birth weight, 56, 59, 131–2, 134, 137, 141, 215
- blackmarkets: alcohol prohibition, 157; cannabis prohibition, 1, 158, 172–5, 190, 224, 234; demand and potency, 133; economic costs, 166, 174; effects, 218–19; gateway hypothesis, 105; legal markets and, 197–200, 203–12, 221, 223, 225; violence and crime, 125, 238–9
- blood, 16–17, 42–5
- blood pressure, 39, 65, 135, 215
- bongs (water pipes), 14, 17, 25
- brain function, 16–17, 82, 84–5, 135, 150, 216
- bronchitis, 62–5, 131–2, 135–7, 141, 215
- C**
- caffeine use, 98
- Canada: cannabis dependence, 74; cannabis use in, 22–3, 26–9; driving accidents, 42; enforcement of prohibition, 165–6, 168, 170–1, 178–9; health costs, 139; medical uses, 233–4; policies, 1, 187, 197, 203; psychological effects, 81; schizophrenia, 99; taxation, 199, 207
- cancer *see* carcinogenicity; chemotherapy
- cannabidiol (CBD), 149–50
- cannabinoid receptors, 16–17, 50, 72, 86, 132, 147, 151, 216
- cannabinoids: absorption, 14–16; biology, 16–17; cancer, 46–7, 58; cannabis plant, 13; cardiovascular effects, 60–1, 65, 134; cognitive functioning, 80, 216; detection in bodily fluids, 15–16, 83; endogenous, 16–17; gastrointestinal effects, 65;

- immunological effects, 50–2, 214; medical uses (*see* medical uses); metabolism of, 15; motor accident drivers and victims, 42–3, 45, 214; pharmaceutical, 147–8, 153, 227–8, 230, 235; pharmacology, 110–11; physical effects, 39; potency (*see* potency); psychoactive effects, 13, 17, 87; psychomotor effects, 41–4; psychotic disorders, 99; reproductive effects, 53–5, 57, 59, 214; storage in body, 132–3, 236; tolerance and withdrawal, 72–3, 215; *see also* metabolites
- cannabis abuse, 73, 109, 123, 138–9, 143, 207, 209
- cannabis dependence, 70–8; adolescents, 75–6, 78, 125; consequences, 75–6; crime, 238; depression, 143; genetic vulnerability, 109; long-term users, 74, 141; policy and, 223–4; psychotic disorders, 90, 95; public health, 138–9; research, xiii, 73–4; risk, 74–5, 131–4, 137–8, 209, 215; suicide, 123; symptoms, 78; syndrome, 215; treatment, 76–8, 138, 215, 222; violence, 125
- cannabis products, 185, 210
- ‘cannabis psychosis’, 87, 88–9, 99
- cannabis smoke: immunological effects, 50, 52, 214; mutagenic and carcinogenic substances, 47, 58, 61–2, 64–5, 214, 228; respiratory effects, 61–5, 134, 215
- cannabis smoking, 6, 14–17, 25, 38; cancers, 47–9; cardiovascular effects, 60–1; heart rate, 39, 65; medical uses, 148, 151, 227–8, 230, 232–4; mortality, 43–4; respiratory effects, 61–5; withdrawal, 73; *see also* cannabis smoke
- car driving *see* driving
- carbon monoxide, 61, 63
- carcinogenicity: alcohol, 135; chronic cannabis use, 46–50, 131, 214–15; lung cancer, 65; respiratory cancers, 61–2, 64–5, 136–7, 141, 215; smoke, 58, 228; tobacco, 135–7
- cardiovascular effects, 39, 60–1, 65, 132, 134–6, 138, 142, 215
- Caribbean, 28, 70, 87–8; *see also* Jamaica
- causal inferences: crime, 236; educational performance, 116–17, 119; health effects, 6–7, 33–6, 37, 130, 134; psychological effects, 69; psychotic disorders, 87, 88, 137; social policy, 7; *see also* gateway hypothesis
- CBD (cannabidiol), 149–50
- cellular effects of chronic cannabis use, 46–50, 214
- chemotherapy, 65, 147–8, 153, 181, 219, 232–3
- children: behaviour, 58–9, 75, 106, 215, 239; cancers, 49–50, 58; conduct disorder, 125; development, 57–8, 81, 215; regulation of sales to, 172–3, 177
- chronic cannabis use: cognitive functioning, 79–81, 119; dependence, 74; health effects, 49–65, 131, 214–15; legalisation, 212; metabolism of cannabinoids, 15; prohibition and, 159, 186; psychological effects, 3, 67–100
- chronic health effects, 36–7, 131, 134–6
- cigarettes *see* tobacco
- civil sanctions, 185, 187, 190–4, 196, 212, 220–1
- cocaine *see* hard drugs (heroin and cocaine)
- cognitive effects, xii, xiii, 38, 69, 72, 75, 79–86, 87, 131, 134–5, 213, 215–16; adolescents, 118–20, 125, 132; early childhood, 58–9
- complementary drug use, 36–8, 56, 79–80, 83, 88, 93–5, 115, 144, 146, 153, 174, 208, 219
- conduct disorder, 122, 125
- confusion, 79, 88–9
- controlled substances, 188, 229
- corruption, 157, 172, 173, 218
- Costa Rica, 52, 60, 70, 79
- costs *see* economic costs
- crime: adolescents, 103, 105, 107, 124–5, 216; blackmarkets, 172–3, 218; cannabis use and, xiii, 236–9
- criminal justice resources: alternative market regimes, 9, 170, 193–4, 207, 212, 220; enforcement of prohibition, xi, 166, 175, 218
- criminal records, 1, 177–8, 187, 192, 194, 218, 224
- criminal sanctions, 1, 6, 185, 224; deterrence, 2, 160–2, 163–4, 169, 217; drug substitution, 146; economic studies, 111; enforcement costs, 166, 168–70, 176, 218; injustice and disproportion, 177–8; legal markets, 209–10, 212, 220, 222; medical use, 234; partial decriminalisation, 191–3, 196, 221, 229; prohibition models, 187–9, 194; *see also* decriminalisation
- cross-national comparisons, 7, 79–80, 146, 153

- Cuba, 188
 cultivation: legal markets, 195–200, 202–4, 206–7; prohibition, 159, 162, 167, 170, 173–4, 185, 193, 239; *see also* home cultivation
- D**
 daily use *see* frequency of use; heavy users
 death *see* dosage; mortality
 decriminalisation: crime and, 237; deterrence and, 220; drug substitution, 144–6; enforcement costs, 166, 169–70, 175; models, 187, 190–4, 196–7; policy debate, x, 2–3, 213, 217, 225, 232–3; reducing harms of use, 221–2; reform options, 219–20; supply, 221; use and, xi, 161–2, 175
 delinquency, 58, 106, 117–18, 124–5, 239
 delusions *see* psychotic disorders
 demand, 112, 133, 144–6, 163, 166, 197–8, 201–2, 206–8, 219
 Denmark, cannabis use in, 25, 28
 dependence *see* cannabis dependence; drug dependence
 depression, 36, 38, 70, 73, 91, 95, 98, 121–3, 143–4
 deterrence: adults, 164; criminal sanctions, 2, 160–4, 179; decriminalisation and, 177, 208, 220, 225; prohibition of cannabis and, 157–9, 217–18
 developmental effects, xi, 55–9, 101–25, 222, 224
 deviant behaviour, 75, 105–6, 116–18, 125, 216
 diathesis *see* genetic vulnerability
 disrespect for law, 7, 9, 60–1, 157–8, 179, 181, 215, 218, 224–5
 distress, 45, 75, 121–2, 143
 distribution *see* supply
 dopamine, 99
 dosage, 14; acute effects, 36, 38, 213; cardiovascular effects, 60; cognitive functioning, 80; fatal overdoses, 17, 39, 45, 134, 213; health effects, 37, 51–2, 214; medical uses, 149; pharmacology, 110, 114; psychomotor tasks and, 45; toxic, 6, 39; withdrawal, 73
 driving: accident risk, x, 39, 42–5, 124, 131, 133–4, 136, 141, 144, 208–9, 214, 224; inappropriate use of cannabis, 140, 164; psychomotor effects on, 16, 39, 40–2, 45, 213–14; regulation, 177, 197, 201–2, 209, 221; self-reported accidents, 44–5
 dronabinol (Marinol), 65, 148, 227, 230
 drop-outs, 106–7, 115, 119–20, 216; *see also* educational performance
 drug abuse, 91–3, 97–8, 109, 138, 188
 drug dependence, 71–2, 75–8, 98, 124, 132, 189–90; *see also* genetic vulnerability; tolerance; withdrawal
 drug education *see* health education
 drug interactions, 36; *see also* complementary drug use
 drug policy *see* policy
 drug subculture, 112, 114, 216
 drug substitution, 144–6, 153, 219
 DSM-IV, 71–2
 duration of use, 6, 37, 80, 85, 140, 164, 186
 dysphoria, 36, 38, 131
- E**
 econometric evidence, 144, 153, 219
 economic costs: drug abuse, 138–9; enforcement of prohibition, 158, 165–75, 181, 217–18, 220, 225
 economic studies: cannabis as gateway drug, 111–12; legal markets, 195, 198–200, 223
 economic substitution, 144–6, 153, 219
 economically motivated crime, 237–8
 educational performance, 25; adolescent cannabis use, xiii, 22, 70, 103, 106, 115–20, 125, 131–2, 135, 224; cannabis dependence, 75; cognitive functioning, 79–80; early school-leaving, 106–7, 115, 119–20, 216; explanations of relationships with cannabis use, 34, 116–17; longitudinal studies, 117–19
 Egypt, 76, 79, 87
 emetic use *see* anti-emetic use
 employment, 25, 70, 75, 131, 135, 178, 187, 198, 218; adolescents, 103, 115, 118–21, 125
 endogenous cannabinoids, 16–17
 enforcement: cost of prohibition of cannabis supply, 165–8, 170–2, 173–5; cost of prohibition of cannabis use, 165, 166–70, 175; costs, 165, 166–70, 175, 181, 186, 220, 225, 234; costs and legal markets, 208, 209–10, 221, 224; drug substitution, 145; economic costs, 158, 165–75, 181, 217–18,

- 220, 225; legal markets, 196–201, 205, 209–12; medical uses, 234; policy of non-enforcement, 195–6; resources, 185; social costs, 218; unequal application, 169, 178–9, 181, 218; variations, 161–4, 188–9, 194
- epilepsy, 149–50, 233
- ethnicity, 146, 153, 178
- euphoria (high), 14, 36, 38, 60, 87, 98, 110, 142, 147, 176, 219
- Europe: cannabis dependence, 76; cannabis use, xi, 4, 25–9; policies, 165–7, 171, 193
- experimentation, 143–4, 164, 190, 223
- exposure opportunities, 108, 112–13, 190, 205, 211
- F**
- faintness, 39
- family circumstances, 29, 92, 107, 117–19, 163, 216
- family history *see* genetic vulnerability
- females: cancers, 48; cannabis dependence, 74, 76; educational performance, 115, 118; mental health, 123, 144; patterns of use, 21–4, 27; reproductive effects, 54, 59, 214–15 (*see also* pregnancy)
- fines *see* civil sanctions
- Finland, 25, 28
- flashbacks, 36, 132
- foetal development, 55–7
- food *see* appetite stimulation; oral administration
- France, 25, 28, 44, 96, 167
- frequency of use, 6, 85, 133, 140, 164; crime, 237; drug substitution, 146; employment, 120; gateway hypothesis, 107–8; health effects, 37; psychological effects, 80; suicide, 123; *see also* heavy users
- G**
- gaol *see* criminal sanctions
- gastrointestinal effects, 65, 135, 215
- gateway hypothesis, x, 103, 104–14, 125, 216; causal explanations of association, 105–14, 174; economic studies, 111–12; exposure opportunities, 112–13; genetic vulnerability to drug dependence, 106–9, 114; pharmacological hypotheses, 110–11, 114; selective recruitment, 106–9, 114; social environmental hypotheses, 112–14
- gender *see* females; males
- genetic vulnerability: drug dependence, 105, 106–9, 114, 216; psychosis (diathesis), 88–9, 97, 99, 131, 135
- Germany, x, 28, 161, 167, 191, 192, 237–8
- glaucoma, medical use of cannabis for, 149, 228
- government monopolies, 203–4, 206, 211, 224
- Greece, 28, 52, 79–80
- growth *see* developmental effects
- H**
- hallucinations *see* psychotic disorders
- hallucinogens, 37, 91, 97, 104, 109, 112–13, 133, 216
- hard drugs (heroin and cocaine): cardiovascular effects, 61; crack epidemic, 157; crime and delinquency, 124, 236–9; dependence, 71, 89; economic costs, 139; education, 180, 219; enforcement, 169, 171–4; evaluation of health risks, 5; international agreements, 1; patterns of use, 22, 105, 132; pregnancy, 81; psychotic disorders, 97; public health, 139–40; *see also* complementary drug use; drug substitution; gateway hypothesis
- harms of cannabis use, 9, 186; decriminalisation and, 1–3, 221–2; legalisation and, 211–12, 223–4; *see also* adverse health effects; cannabis abuse; cannabis dependence
- hash (hashish), 13–14, 17, 79, 192
- hash hungries *see* appetite stimulation
- hash oil, 13–14, 17
- health costs, 9, 139, 212; *see also* health service utilisation; public health
- health education, 3, 187, 190–2; cost of prohibition, 179–81, 219, 224; law reform, 140, 201, 221, 224–5
- health effects, x, xii, 1–4, 129, 213–17; alcohol and tobacco compared with cannabis, 129, 130–41; indirect, 131; policy and, 213, 216–17, 221–6; research, 5–7, 35, 37, 130, 139, 221–2, 225; *see also* adverse health effects
- health service utilisation, 43–4, 52, 59, 97, 121, 208
- heart conditions *see* cardiovascular effects

- heart rate, 16, 39, 60–1, 65, 215
- heavy users, 14, 186; cardiovascular effects, 60; cognitive effects, 80–1, 85, 125; gender, 27; legalisation, 212
- heroin *see* hard drugs (heroin and cocaine)
- high *see* euphoria
- HIV-AIDS: AIDS-related deaths, 44, 48, 53; immunological effects, 53, 59, 214; injecting drug users, 189; medical use, 65, 148–9, 154, 180–1, 215, 219, 228, 230, 232–3
- home cultivation: law reform, 169, 196, 200, 203, 207, 210–11, 221, 225; medical use, 229–31, 233–4
- homosexual men, 44, 53, 59, 149
- hospitalisation *see* health service utilisation
- hypertension, 60, 65, 132, 215
- hypnotic effects, 147
- I**
- illicit drugs *see* hard drugs (heroin and cocaine)
- immunocompromised persons, 53, 59, 148–9
- immunological effects, 17, 37, 50–3, 58–9, 214
- importation and smuggling, 170–1, 188, 190, 195, 199, 207
- India, 4, 14, 87–8, 146
- individual characteristics *see* personality and attitudinal traits
- individual liberty *see* liberty
- industrial hemp, 168, 196–7, 207
- infectious diseases, 52, 58, 149, 214
- information processing, 81–3, 119, 215
- injection, 14, 147
- international agreements, 1, 7, 195, 222–3, 225
- international comparisons *see* cross-national comparisons
- interpersonal relationships, 103, 121
- intoxicants, 6, 106, 114
- intoxication, 6, 17; acute effects, 131–5, 213–14; adolescents, 103, 119, 125, 132, 209; alcohol, 42, 45, 157; cannabinoids, 16–17, 132–3; chronic, 120; delinquency, 124; psychological effects, 38, 71–2, 74–5, 80; psychomotor effects, 39–42; rates of use, 186
- IQ, 57–8, 81, 83, 93
- Ireland, 28
- Italy, 166, 193
- J**
- Jamaica, 14, 28, 52, 60, 70, 79–80
- joints, 14, 17, 25
- L**
- law reform *see* policy
- learning, 83, 115
- legal markets, 185–6, 211–12, 217; effects on use, 198–201, 223; enforcement, 168, 174; monetary price, 205–7; potential models, 195–7, 198; regulation and social norms, 201–7; social costs, 207–10; social costs of enforcement, 209–10; social costs of use, 208–9
- legal risk, 135, 160–2, 172, 174, 199–200, 207
- legalisation: alcohol and tobacco compared with cannabis, 129; *de facto*, 194; enforcement costs, 175; legal obstacles to, 222–3; medical uses, 227–9, 234; policy debate, 195–212, 213, 222, 225; proposals for, 2, 197–201; public health, 140; rates of use and, 223; reducing harms of use, 223–4
- liberty, 7–8, 158, 176–7, 181, 219, 224–5
- licensing systems, 196–7, 203–4, 206–7, 210–11, 221, 224
- liver function, 65, 135, 157, 208, 215
- long-term effects *see* chronic health effects
- long-term users *see* chronic cannabis use
- lung cancer, 47, 62, 65, 137
- lungs, effects on, 52, 62–3, 65, 135, 151, 214, 228
- M**
- males: cancers, 48; cannabis dependence, 74, 76; cognitive functioning, 79; delinquency, 124; educational performance, 115, 118; patterns of use, 22–5, 27–8, 90; reproductive effects, 54–5, 59, 214–15; self-harmful behaviour, 123
- marijuana, 13–14, 17
- Marinol (dronabinol), 65, 148, 227, 230
- markets *see* blackmarkets; legal markets
- marriage, 21–2, 29, 120–1
- medical care *see* health service utilisation
- medical uses: benefits, 129, 146–54, 219; biology, 17; debate on, 4, 227–35; history, 14; initiatives, x, 188, 193, 229–32, 233–4;

- loss of, under prohibition, 7, 180–1, 224;
obstacles to, 153, 234–5; psychological
effects, 38; registration for, 228–9, 231; *see*
also appetite stimulation
- memory, 17, 38, 58, 76, 79–80, 83, 85, 87–9,
115, 131, 135, 213, 215
- mental health, xii, 87; adolescents, 103, 117,
121–3, 125, 216; benefits of cannabis use,
142–4, 153, 219; *see also* psychotic
disorders
- metabolites, 15–17, 42, 44
- Mexico, 188
- Middle East, 146
- monetary costs *see* economic costs
- monetary price *see* price
- monopolies, 203–4, 206, 211, 224
- mood, 17, 39, 73, 122, 143
- moral theories, 5–6, 8–9
- morbidity, 130, 138–40
- mortality, 43–4, 130, 135, 138–9, 142, 208,
213–14, 222
- motivational effects, 69–71, 75, 78, 119
- motor performance, 17, 38, 150–1
- motor vehicle accidents *see* driving
movement disorders, 149, 150–1
- multiple sclerosis (MS), 149–51, 180–1,
232–3
- munchies *see* appetite stimulation
- muscle spasticity *see* anti-spasmodic use
- mutagenicity, 46–50, 58, 64
- N**
- nabilone, 227
- narcotic drugs, 1, 91, 124, 147
- nausea *see* anti-emetic use
- Netherlands, xi, 7, 28, 94, 161, 163, 194–6,
204, 222–3, 237–8
- neural systems, 39, 110, 114, 151
- neuroleptic drugs, 87, 92, 96, 99
- neurological disorders, 149–51, 180–1, 232–3;
see also anti-spasmodic use
- neurotoxicity, 84–5
- New Zealand: adolescent cannabis use, 105–7,
113, 116–17, 122, 125; cannabis
dependence, 74; driving accidents, 45;
enforcement, 178; mental health, 143;
psychotic effects, 88–9, 95; respiratory
effects, 64
- nicotine *see* tobacco
- Norway, 26, 28
- O**
- occupational performance *see* employment
- Oceania, 26–7
- opiates, 72, 79, 107, 138–9, 147
- opioids, 6, 71, 109–11, 114, 151
- opportunity costs, 166, 170
- oral administration, 14–15, 38, 73, 140, 147,
149, 151, 227–8
- overdose *see* dosage
- P**
- pain modulation *see* analgesic effects
- panic, 36, 38, 131, 209, 213
- paranoia, 131
- parents *see* family circumstances
- peer groups, 107–8, 112–15, 117–18, 120–1,
124–5, 216
- penalties, 7, 162–3, 185, 188–94, 208, 218,
220, 222; *see also* civil sanctions; criminal
sanctions; treatment
- perceptual alterations, 38, 58, 96
- personality and attitudinal traits, 103, 105–8,
112, 114, 117, 131, 134, 239
- pharmaceutical drugs, 65, 147–8, 153, 188,
227–8, 230, 235
- pharmacology: effects, 6, 237–8; gateway
hypothesis, 105, 110–11, 112, 114, 174,
216; medical uses, 151, 153
- ‘pills’ *see* amphetamines; tranquillisers
- policing: enforcement of prohibition, 167–71,
175, 189–90, 217–18, 224; legal markets,
193–4, 199–200, 209, 212; quality-of-life,
168, 171, 209
- policy: alternatives, 7, 9, 172, 183–226 (*see*
also decriminalisation; legalisation;
prohibition of cannabis); changes, 144,
161–2, 175; choice of evils, 224–6; debate,
xii, 1–5, 7–9, 129, 157–8, 179, 181, 187,
213, 225–6; drug involvement patterns,
105; economic studies, 111; effect on use,
161–3; health effects and, 216–17;
prevention, 111; reform, x, 157, 219–24;
research, 4, 226; simplifications, 2–3, 213,
216, 226
- Portugal, 28, 166–7, 193–4
- possession: legal, 195, 197, 202, 208, 225;
offences, xi, 159–62, 165–9, 175, 185,
187–94, 196, 222, 229, 237
- potency, 14, 17, 173, 197, 205, 218, 221, 223;
control, 204, 209; increases in, 13, 132, 133

- poverty *see* socioeconomic status
- pregnancy: alcohol use, 134; cannabis use during, 21–2, 49–50, 54–9, 81, 131–2, 134, 137, 141, 214–15; health education, 201; inappropriate use of cannabis, 164; teenage, 106, 119–21; *see also* birth defects; birth weight
- premature death *see* mortality
- prevention studies, 111
- price: blackmarkets, 161–2, 172, 211, 238; economic studies, 111, 144–6; legal markets, 9, 174–5, 198–200, 205–7, 208–12, 223
- prohibition of alcohol, 7, 157–8, 188, 190
- prohibition of cannabis: benefits, 157–8, 163–4; complete, 187–90; costs, 163–4, 176–81, 213, 217–20, 224–5; crime, 236, 238; deterrence and, 175, 179, 217–18, 220; enforcement (*see* enforcement); impact on use, 159–64; medical use and, 227; policy, 1–3, 6–7, 157, 185, 194, 198, 209, 211, 213; public health, 140, 216–17; social costs, 157–8; variants, 185, 187–94
- psychiatric disorders, 70–2, 81–2, 89, 91–5, 121, 123–4, 135
- psychoactive drugs, 6, 22, 71, 130
- psychoactive effects, 4, 13, 15–17, 36, 51, 87–91, 148, 151–2, 236
- psychological effects, 17, 129, 131–3, 221–3; acute, 38, 45, 119, 213–14; adolescents, 35, 103, 115–25, 216; animal studies, 34; chronic cannabis use, 67–100, 213–16; *see also* cognitive effects
- psychomotor effects, 16–17, 38, 45, 72, 119, 131, 134, 209, 213–14
- psychopharmacology, 236–7
- psychostimulants, 6, 75, 91, 96–7, 109–10, 123
- psychotic disorders: acute effects of cannabis use, 36, 38, 131, 213; adolescents, 121–2; alcohol, 157; causal inferences, 87, 88; chronic cannabis use, 69, 87–100, 135, 216; regulation, 209, 222–4; symptoms, 89–90, 99; treatment, 97; vulnerability to, 95–6, 99, 131, 216; *see also* 'cannabis psychosis'; schizophrenia
- public education *see* health education
- public health: burden of disease, 139–40; changes in prevalence of cannabis use, 140; current patterns of use, 141; immunological effects, 50, 52; impact of alcohol, tobacco and illicit drugs, 129–30, 136–7, 138–40, 144; policy, 6, 205
- public policy *see* policy
- Q**
- quality control, 9, 172–3, 177, 209, 222
- R**
- race and ethnicity, 146, 153, 178
- rates of use: decriminalisation and, 220, 225; Europe, xi; legalisation and, 140, 197–8, 200, 204, 207–8, 211–12, 223; policy and, 159, 162–3, 168–9, 171, 186
- receptors *see* cannabinoid receptors
- recreational use: benefits, ix, 129, 142–6, 153, 176, 219; biology, 17; dysphoric effects, 36, 38, 131; effects sought, 36, 38; enforcement of prohibition, 168–9; history, 21–2, 29, 188; legalisation, 198, 208; medical use and, 147, 149–50, 227–9, 232, 234; policy, x, 4, 129
- registration for medical use, 228–9, 231
- regulation, 9, 173–5, 177, 185–6, 198–207, 208–10, 212, 221–2, 224–5; *see also* licensing systems
- relaxation, 36, 38, 142, 176, 213, 219
- reproductive effects, 17, 53–8, 214–15
- reputation *see* criminal records
- respect for law *see* disrespect for law
- respiratory tract: cancers, 48, 58, 64, 136–7, 141, 214–15, 222; effects on, 17, 52, 59, 61–4, 131–7, 141, 215, 222, 224; health education, 201, 221
- retail markets, 173–4, 194–6, 203–4, 223, 225
- risk-taking behaviour, 107, 118, 140
- risks of cannabis use, 130, 136–8
- S**
- sale *see* supply
- schizophrenia, 69, 89; association with cannabis use, 87–8, 91–2; exacerbation, 96–7, 99, 132; health education, 201; precipitation of, 92–6, 99, 132, 135, 216; research, 90–1, 98–9; risks, 94, 132, 137, 141; self-medication, 98; treatment, 99; violence, 125
- school leaving, 106–7, 115, 119–20, 216; *see also* educational performance
- sedatives, 91, 109, 123
- selective recruitment, 106–8, 114
- self-esteem, 75–6, 107

- self-medication, 98, 122
- sensitisation *see* pharmacology
- sequence of drug use *see* gateway hypothesis
- sexual behaviour, 38, 53, 105–7, 118–19
- smoking *see* cannabis smoking; tobacco
- smuggling *see* importation and smuggling
- sociability, 38, 98, 114, 142, 176, 213, 219
- social costs: cannabis-control policies, 7–9, 186, 191; comparisons with alcohol and tobacco, 138; enforcement of prohibition, 165, 171–3, 217–18; law reform, 2, 197–8, 200–1, 207–10
- social environment: cannabis as gateway drug, 105, 109, 112–13, 114; educational performance, 117, 120, 125; interpersonal relationships, 121; suicide, 123
- social norms: health education, 180, 190; legal markets and regulation, 140, 197–8, 200, 201–7, 212, 222–3, 225–6; regulating demand, 163, 201–2; regulating supply, 202–5; values, 8–9
- social performance *see* psychological effects
- social policy *see* policy
- socioeconomic status, 28, 70, 107, 117, 123, 178
- South Africa, 88
- South America, 26–8
- Spain, 25, 28, 166, 193
- special case, cannabis as, 3, 6
- spinal cord injuries, 149–50, 233
- stepping stone hypothesis *see* gateway hypothesis
- stimulants, 6, 75, 91, 96–7, 109–10, 123
- subculture, 112, 114, 216
- substance dependence *see* drug dependence
- substitution, 144–6, 153, 219
- suicide, 122, 123–4, 134–5
- supply: law reform, 161, 185–6, 195–9, 202–6, 220–2, 224; medical uses, 234; prohibition, 159, 175, 185, 187–8, 190, 193, 195–6, 234 (*see also* enforcement); *see also* cultivation
- Sweden, 25, 28, 43, 88, 92–4, 179, 187–8, 189–90
- Switzerland, x, 25–6, 122, 143, 167–9, 178, 194, 197, 205, 207; *de facto* legalisation, 196
- T**
- taxation: blackmarket and, 166, 172, 174–5, 219, 225; economic studies, 111, 144; legal markets, 199–200, 206–7, 211, 222–3
- THC *see* cannabinoids
- thinking *see* cognitive effects
- tobacco: deaths caused by fires, 131; dependence, 75, 78, 109; drug substitution, 146; gateway hypothesis, 104, 106–7, 110–11, 113, 216; health effects, 6, 37, 44, 47–50, 61–4, 129, 130–41, 215, 217, 221; market regulation, 199, 201–2, 205, 207–8, 222; mental health, 90, 98, 121–2; patterns of use, 21–2, 160, 211; policy, 3, 223–4; pregnancy, 215; price, 212; risks, 141; smoke, 47, 58, 131, 134, 214–15; used with cannabis, 14, 56–8, 84
- tolerance of effects, 52, 58, 60–1, 71–4, 78, 133, 149, 214–15
- toxicity *see* dosage
- tranquillisers, 37, 93, 104, 112–13, 216
- treatment, 185, 187, 189–94, 220
- tremors and startle, 57–8, 150–1
- U**
- unemployment *see* employment
- United Kingdom: cannabis use in, xi, 25–6, 28, 159–60; crime, 236; medical uses, 147, 227–8, 232, 234–5; policies, 1, 166–7; psychotic effects, 88; reproductive effects, 56
- United States: adolescent cannabis use, 103–5, 112–13, 115, 118, 122–4, 211; alcohol prohibition, 7, 157; cannabis dependence, 73–4, 76, 78, 137–8; cannabis prohibition, 187, 188–9; cannabis use, 4, 18–19, 18–22, 19–23, 26–9, 145, 159–63, 208; crime, 236–9; driving accidents, 42; drug dependence, 78; drug substitution, 145–6; federal–state conflicts, 192–3, 229–32, 234; health effects, 53, 131; health service use, 208; home cultivation, 210, 229–31; medical uses, x, 147–9, 180–1, 227–8, 229–32, 234–5; policies, x–xi, 1, 165–8, 170–5, 178–9, 187–9, 191–3, 197–205, 220; potency of cannabis, 13, 133; psychological effects, 70, 79, 99, 143–4; taxation, 207
- urine, detection of cannabinoids in, 16–17, 83
- use: controlling, 78; costs of, 186; crime and, 236–9; discontinuance, 75, 159; duration (*see* duration of use); experimentation, 143–4, 164, 190, 223; factors associated with, 26–8; frequency (*see* frequency of use); inappropriate, 164; law reform, 163,

Cambridge University Press

978-0-521-80468-4 - Cannabis Use and Dependence: Public Health and Public Policy

Wayne Hall and Rosalie Liccardo Pacula

Index

[More information](#)**298** **Index**

198–201, 208–9, 222; measuring, 18–26; occasional and intermittent, 23, 159, 164, 192, 194, 208; offences, x, 175; patterns of, 18–29, 105, 133, 140–1, 178, 198, 223; prohibition, 159–64, 185, 187–94 (*see also* enforcement); rates (*see* rates of use); research on, 4; restrictions on, 197, 202; trends, 18, 20, 23–5, 140; *see also* benefits of cannabis use; harms of cannabis use; possession

V

values, 8–9

violence and aggression: alcohol use, 131, 134–5, 144, 237; cannabis use, 96, 124–5, 236–7; market-related, 166, 172, 238–9; withdrawal, 73

visual system, 57–8; *see also* glaucomavomiting *see* anti-emetic usevulnerability *see* genetic vulnerability**W**

water pipes (bongs), 14, 17, 25

weight gain *see* appetite stimulation

withdrawal, 71–4, 76–8, 134–5, 138, 215, 238

Y

young adults: cancer, 214; cannabis dependence, 78; cannabis use, 1, 18–29, 188; cardiovascular effects, 60–1, 215; drug substitution, 144–6; employment, 120–1; gateway hypothesis, 105, 112–13; interpersonal relationships, 121; legalisation and use, 212; mental health, 122–3, 144; prohibition and, 159–60; public health, 50, 141; reproductive effects, 53–4; respiratory effects, 62–3; schizophrenia, 99; *see also* disrespect for law

youth *see* adolescents